428Pharma is developing Escitalopram LAI, the first long-acting injectable formulation of an SSRI, utilizing a novel salt to enhance patient adherence in the treatment of depression. This approach targets the significant market gap in long-term depression management, with an estimated peak sales potential exceeding $1.5 billion in the US and EU.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients with depression struggle with adherence to daily oral antidepressant medications, leading to suboptimal treatment outcomes and increased risk of relapse. The inconvenience of daily dosing, coupled with potential side effects, contributes to poor compliance and reduced effectiveness of selective serotonin reuptake inhibitors (SSRIs).
Solution
428Pharma is developing Escitalopram LAI, a long-acting injectable formulation of escitalopram, an SSRI, designed to improve patient adherence and maintain stable drug levels. By utilizing a novel salt formulation, Escitalopram LAI aims to provide sustained release of the medication over an extended period, potentially reducing the burden of daily dosing and improving therapeutic efficacy. This approach addresses the need for more convenient and reliable treatment options for individuals with depression, offering a way to overcome the challenges associated with oral medication adherence.
Target Audience
The primary target audience includes individuals diagnosed with depression who struggle with adherence to daily oral antidepressant medications, as well as psychiatrists and other healthcare providers seeking to improve treatment outcomes through enhanced medication adherence.
Features
- Long-acting injectable formulation of escitalopram for sustained drug release
- Utilizes a novel salt to enhance the pharmacokinetic profile of escitalopram
- Aims to reduce the frequency of dosing compared to daily oral medications
- Designed for subcutaneous or intramuscular administration by a healthcare professional
- Intended to improve patient adherence and maintain stable therapeutic drug levels
- Targets the large depression market with an estimated value of $15.8 billion in 2025
- Pursuing a 505(b)(2) regulatory pathway for efficient development